The biomedical use of nanoparticles (NPs) has been the focus of intense research for over a
decade. As most NPs are explored as carriers to alter the biodistribution, pharmacokinetics …

Introduction Most lung diseases are serious conditions resulting from genetic and
environmental causes associated with high mortality and severe symptoms. Currently …

mRNA-based vaccines and candidate therapeutics have great potential in various medical
fields. For the delivery of mRNA into target cells and tissues, lipid formulations are often …

For cystic fibrosis patients, a lung-targeted gene therapy would significantly alleviate
pulmonary complications associated with morbidity and mortality. However, mucus in the …

Pseudomonas aeruginosa (P. aeruginosa) pneumonia can have serious physiological
consequences, particularly when P. aeruginosa biofilms are formed. Although inhaled …

In the vanguard of biomedical innovation, regenerative medicine emerges as a
transformative paradigm, concentrating its efforts on rectifying tissue deficits and functional …

Pulmonary delivery of therapeutic agents has been considered the desirable administration
route for local lung disease treatment. As the latest generation of therapeutic agents, nucleic …

Nucleic acid-based drugs are changing the scope of emerging medicine in preventing and
treating diseases. Nanoparticle systems based on lipids and polymers developed to …

Gene editing strategies are attractive for treating genetic pulmonary diseases such as cystic
fibrosis (CF). However, challenges have included the development of safe and effective …

Abstract Background Cell-penetrating peptides (CPPs) are short sequences of amino acids,
typically ranging from 5 to 30 residues, known for their ability to penetrate cell membranes …